iBio

iBio develops plant-based biologics, therapeutic proteins and vaccines for the treatment of fibrotic diseases. Read more

Thomas F. Isett's photo - Chairman & CEO of iBio

Chairman & CEO

Thomas F. Isett

CEO Approval Rating

86/100

Founded:

1993

Status:

PublicIndependent CompanyNYSEIBIO

IBIO TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Protalix is a top competitor of iBio. Protalix was founded in 1992, and is headquartered in Karmiel, North District. Like iBio, Protalix also competes in the Biotechnology field. Protalix generates $20.9M more revenue vs. iBio.

KBI Biopharma is seen as one of iBio's top competitors. KBI Biopharma is headquartered in Durham, North Carolina, and was founded in 1996. Like iBio, KBI Biopharma also operates in the Biotechnology field. KBI Biopharma generates 2,076% the revenue of iBio.

Tedor has been one of iBio's top competitors. Tedor's headquarters is in Cumberland, Rhode Island, and was founded in 2001. Like iBio, Tedor also works within the Biotechnology industry. Tedor generates 166% of iBio's revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Batavia Biosciences a competitor of iBio?

iBio Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$3M

iBio's revenue is the ranked 13th among it's top 10 competitors. The top 10 competitors average 58.9M. Over the last four quarters, iBio's revenue has decreased by 31.7%. Specifically, in Q1 2021's revenue was $ < 1M; in Q4 2020, it was $ < 1M; in Q3 2020, it was $ < 1M; in Q2 2020, iBio's revenue was $1.1M.

iBio Acquisitions

No recent acquisitions found related to iBio

iBio Funding History

Since iBio was founded in 1993, it has participated in 3 rounds of funding. In total iBio has raised $12.2M. iBio's last funding round was on Jan 2016 for a total of $2.2M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Jan 2016
$2.2M
-
Equity
Oct 2010
$7.1M
-
Equity
Sep 2009
$3M
-

Since iBio was founded in 1993, it has participated in 3 rounds of funding. In total iBio has raised $12.2M. iBio's last funding round was on Jan 2016 for a total of $2.2M

iBio Investments

No recent investments found related to iBio

iBio News

May 10, 2021MarketScreener

iBio to Report Fiscal 2021 Third Quarter Financial Results and Provide Corporate Update on Monday, May 17, 2021

(marketscreener.com) BRYAN, Texas, May 10, 2021 -- iBio, Inc. , a biotech innovator and biologics con... See more »
May 7, 2021Markets Insider

Why Is iBio's Stock Trading Higher Today?

iBio, Inc. (NYSE: IBIO) shares are trading higher after the company provided an update on its IBIO-20... See more »
May 5, 2021Markets Insider

Why Nemaura, iBio And Cocrystal Are Moving Wednesday

Nemaura Medical Inc. (NASDAQ: NMRD), iBio, Inc. (NYSE: IBIO) and Cocrystal Pharma, Inc.... See more »
March 9, 2021Markets Insider

iBio to Participate in the 33rd Annual Roth Conference

BRYAN, Texas, March 09, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a... See more »
December 29, 2020BioTuesdays

iBio names renowned drug discovery and development expert Martin Brenner as CSO

iBio names renowned drug discovery and development expert Martin Brenner as CSO... See more »

iBio Press Releases

November 12, 2020GlobeNewswire

iBio to Participate in Alliance Global Partners' Virtual Healthcare Symposium

BRYAN, Texas, Nov. 12, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a... See more »
October 5, 2020GlobalNewswire

iBio Regains Compliance with NYSE American Continued Listing Standards

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) ("iBio" or the "Company")... See more »
March 17, 2020centralcharts

iBio, Inc. - IBIO Stock Chart Technical Analysis for 03-17-2020

News videos - iBio, Inc. - IBIO Stock Chart Technical Analysis for 03-17-2020 - Published on 03/17/20... See more »
February 12, 2020centralcharts

iBio, Inc. - IBIO Stock Chart Technical Analysis for 02-11-2020

News videos - iBio, Inc. - IBIO Stock Chart Technical Analysis for 02-11-2020 - Published on 02/11/20... See more »
January 2, 2020centralcharts

iBio, Inc. - IBIO Stock Chart Technical Analysis for 01-02-2020

News videos - iBio, Inc. - IBIO Stock Chart Technical Analysis for 01-02-2020 - Published on 01/02/20... See more »
December 16, 2019StreetInsider

iBio Reports Progress on its Bio-Better Rituximab Collaboration with CC-Pharming

- Presentation Demonstrates Advantages of iBios Recently Launched FastGlycaneering Development Servic... See more »
December 13, 2019StreetInsider

iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance Plan

NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE American: IBIO) (iBio or the Company), a... See more »

Social Media

iBio Headquarters

600 Madison Avenue Suite 1601

New York, New York10022

302-355-0650

Driving Directions »

Trending Companies

iBio Summary

ABOUT

Overview

iBio develops plant-based biologics, therapeutic proteins and vaccines for the treatment of fibrotic diseases. iBio was founded in 1993. iBio's headquarters is located in New York, New York, USA 10022. It has raised 12.2M in 3 rounds. The latest round...

CEO

iBio's Chairman & CEO, Thomas F. Isett, currently has an approval rating of 86%. iBio's primary competitors are Protalix, KBI Biopharma & Tedor.

Frequently Asked Questions about iBio

  1. When was iBio founded?

    iBio was founded in 1993
  2. Who is iBio's CEO?

    iBio's CEO is Thomas F. Isett
  3. How much revenue does iBio generate?

    iBio generates $3M in revenue
  4. How much funding does iBio have?

    iBio has historically raised $12.2M in funding
  1. Where is iBio's headquarters?

    iBio's headquarters is in New York New York, USA
  2. How many employees does iBio have?

    iBio has 1 employees
  3. What sector does iBio operate in?

    iBio is in Biotechnology
  4. Who are iBio's competitors?

    iBio's top competitors are Protalix, KBI Biopharma, Tedor